TSC2 and liver hemangioma: This is in line with the lack of tumor-inhibiting properties of atorvastatin in a mouse model of TSC2-related liver hemangioma [29], but not with data obtained with a MYC-driven HCC mouse model where atorvastatin acted as a tumor-preventive compound [25].